Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Apostolia Maria Tsimberidou; Tracey Waddelow; Hagop M. Kantarjian; Maher Albitar; Francis J. Giles

doi:10.1016/S0145-2126(02)00082-6

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Apostolia Maria Tsimberidou, Tracey Waddelow, Hagop M. Kantarjian, Maher Albitar, Francis J. Giles^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

Original language	English (US)
Pages (from-to)	375-380
Number of pages	6
Journal	Leukemia Research
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/S0145-2126(02)00082-6
State	Published - May 1 2003

Keywords

Enbrel
Multiple myeloma
Refractory
TNFα

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(02)00082-6

Fingerprint

Dive into the research topics of 'Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment'. Together they form a unique fingerprint.

Cite this

Tsimberidou, A. M., Waddelow, T., Kantarjian, H. M., Albitar, M., & Giles, F. J. (2003). Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment. Leukemia Research, 27(5), 375-380. https://doi.org/10.1016/S0145-2126(02)00082-6

@article{077d8d69bb61495fae307dcffd4a45c4,

title = "Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment",

abstract = "Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.",

keywords = "Enbrel, Multiple myeloma, Refractory, TNFα",

author = "Tsimberidou, {Apostolia Maria} and Tracey Waddelow and Kantarjian, {Hagop M.} and Maher Albitar and Giles, {Francis J.}",

year = "2003",

month = may,

day = "1",

doi = "10.1016/S0145-2126(02)00082-6",

language = "English (US)",

volume = "27",

pages = "375--380",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "5",

}

Tsimberidou, AM, Waddelow, T, Kantarjian, HM, Albitar, M & Giles, FJ 2003, 'Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment', Leukemia Research, vol. 27, no. 5, pp. 375-380. https://doi.org/10.1016/S0145-2126(02)00082-6

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment. / Tsimberidou, Apostolia Maria; Waddelow, Tracey; Kantarjian, Hagop M. et al.
In: Leukemia Research, Vol. 27, No. 5, 01.05.2003, p. 375-380.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma

T2 - Increase in plasma TNFα levels during treatment

AU - Tsimberidou, Apostolia Maria

AU - Waddelow, Tracey

AU - Kantarjian, Hagop M.

AU - Albitar, Maher

AU - Giles, Francis J.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

AB - Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

KW - Enbrel

KW - Multiple myeloma

KW - Refractory

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=0037400526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037400526&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00082-6

DO - 10.1016/S0145-2126(02)00082-6

M3 - Article

C2 - 12620287

AN - SCOPUS:0037400526

SN - 0145-2126

VL - 27

SP - 375

EP - 380

JO - Leukemia Research

JF - Leukemia Research

IS - 5

ER -

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this